JNJ Set to Hit $100 Billion Revenue Milestone as Oncology Growth Accelerates

Johnson and Johnson is on track to reach $100 billion in revenue for the first time in its 140-year history, driven by a strong oncology portfolio and steady execution in MedTech.

The company's Innovative Medicine segment generated $16.4 billion in Q2 revenue, up 7.8% year over year, with Darzalex reaching $4.2 billion in quarterly revenue and Tremfya surging 72.5% to $2 billion.

Johnson and Johnson's balance sheet is also strong, with $19.7 billion in cash and equivalents at year-end 2025, and the company generated $11.1 billion in operating cash flow in the first half of 2026.